journal article·2025-12-26Open access

Nanotherapy Targeting miR-10b Improves Survival in Orthotopic Glioblastoma Models

Bryan D. Kim, Ming Chen, Sujan K. Mondal, Elizabeth Kenyon, Christiane L. Mallett, Ana deCarvalho, Zdravka Medarova, Anna Moore

Abstract

Glioblastoma (GBM) is the most aggressive primary cancer with poor survival. In the absence of an effective treatment and a high probability of recurrence, new therapeutic approaches are urgently needed. This study focused on targeting microRNA-10b (miR-10b) highly expressed in GBM cells that has been identified as one of the key drivers of GBM progression. Inhibiting miR-10b using antisense oligonucleotides (ASOs) has shown promise, but its delivery is challenging due to short circulation half-life, degradation by nucleases, and limited blood–brain barrier (BBB) permeability. To overcome these barriers, we employed a magnetic nanoparticle (MN) platform to deliver anti-miR-10b ASOs (MN-anti-miR10b). In addition to serving as a delivery vehicle, these nanoparticles can be used for monitoring delivery using magnetic resonance imaging (MRI). In therapeutic studies in orthotopic models of GBM presented here we used MN-anti-miR10b as well as TTX-MC138, a clinically tested anti-miR10b nanotherapeutic now in Phase I trials in patients with solid (non-GBM) cancers. Both formulations showed efficient delivery, as demonstrated by imaging and improved survival, leading to target inhibition and increased apoptosis. This approach may offer a novel strategy for delivering therapeutics to GBM and improving patient outcomes in one of the most aggressive and treatment-resistant forms of brain cancer.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: MicroRNA in disease regulation · Nanoparticle-Based Drug Delivery · Glioma Diagnosis and Treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Precision Health Program, Michigan State University, East Lansing, MI 48824, USA

Department of Biomedical Engineering, College of Engineering, Michigan State University, East Lansing, MI 48824, USA

Department of Radiology, College of Human Medicine, Michigan State University, East Lansing, MI 48824, USA

Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI 48824, USA

Henry Ford Health, Detroit, MI 48202, USA

TransCode Therapeutics Inc., Woburn, MA 02458, USA

Funding

Henry Ford Health + Michigan State University Health Sciences

References (60)

Show source-provided references
1. Clinical, Therapeutic, and Prognostic Experience in Patients With Glioblastoma
2. Roda, D., Veiga, P., Melo, J.B., Carreira, I.M., and Ribeiro, I.P. (2024). Principles in the Management of Glioblastoma. Genes, 15.10.3390/genes15040501 ↗
3. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data10.1093/neuonc/nox175 ↗
4. The role of MicroRNAs in human cancer10.1038/sigtrans.2015.4 ↗
5. Human glioma growth is controlled by microRNA-10b10.1158/0008-5472.CAN-10-3568 ↗
6. MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD1010.1016/j.brainres.2011.03.013 ↗
7. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC10.1002/ijc.24522 ↗
8. Oncogenic effects of miR-10b in glioblastoma stem cells10.1007/s11060-013-1047-0 ↗
9. Context effect: microRNA-10b in cancer cell proliferation, spread and death10.4161/auto.7.11.17371 ↗
10. MicroRNA-10b pleiotropically regulates invasion, angiogenicity and apoptosis of tumor cells resembling mesenchymal subtype of glioblastoma multiforme10.1038/cddis.2012.134 ↗
11. MicroRNA-10b mediates TGF-beta1-regulated glioblastoma proliferation, migration and epithelial-mesenchymal transition10.3892/ijo.2017.3947 ↗
12. Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: First steps toward the clinic10.15252/emmm.201505495 ↗
13. MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity in glioblastoma10.18632/oncotarget.3009 ↗
14. Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b10.1016/j.ymthe.2016.11.004 ↗
15. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma10.1038/s41591-019-0349-y ↗
16. MicroRNA degradation and turnover: Regulating the regulators10.1002/wrna.1114 ↗
17. Stepanov, G., Zhuravlev, E., Shender, V., Nushtaeva, A., Balakhonova, E., Mozhaeva, E., Kasakin, M., Koval, V., Lomzov, A., and Pavlyukov, M. (2018). Nucleotide Modifications Decrease Innate Immune Response Induced by Synthetic Analogs of snRNAs and snoRNAs. Genes, 9.10.3390/genes9110531 ↗
18. A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery10.3109/10717544.2014.882469 ↗
19. Meng, Z., and Lu, M. (2017). RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant?. Front. Immunol., 8.10.3389/fimmu.2017.00331 ↗
20. Targeted nanoparticle delivery of therapeutic antisense microRNAs presensitizes glioblastoma cells to lower effective doses of temozolomide in vitro and in a mouse model10.18632/oncotarget.25135 ↗
21. Dynamic carriers for therapeutic RNA delivery10.1073/pnas.2307799120 ↗
22. Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells10.1021/acs.molpharmaceut.5b00694 ↗
23. Tailored Nanoparticle Codelivery of antimiR-21 and antimiR-10b Augments Glioblastoma Cell Kill by Temozolomide: Toward a “Personalized” Anti-microRNA Therapy10.1021/acs.molpharmaceut.6b00388 ↗
24. Development and characterization of cationic solid lipid nanoparticles for co-delivery of pemetrexed and miR-21 antisense oligonucleotide to glioblastoma cells10.1080/03639045.2017.1391835 ↗
25. Co-delivery of pemetrexed and miR-21 antisense oligonucleotide by lipid-polymer hybrid nanoparticles and effects on glioblastoma cells10.1080/03639045.2016.1200069 ↗
26. Zhang, Y., Rabinovsky, R., Deforzh, E., Kobayashi, A., Kuzkina, A., Varghese, J.F., Rai, D., Korecka, J.A., Khurana, V., and Murugaiyan, G. (2025). Lipid nanoparticle formulation for gene editing and RNA-based therapies for glioblastoma. Neuro Oncol., noaf162.10.1093/neuonc/noaf162 ↗
27. Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites10.1038/s41467-022-31322-3 ↗
28. Chen, M., Kim, B., Robertson, N., Mondal, S.K., Medarova, Z., and Moore, A. (2023). Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells. Front. Mol. Biosci., 10.10.3389/fmolb.2023.1179343 ↗
29. Savan, N.A., Saavedra, P.V., Halim, A., Yuzbasiyan-Gurkan, V., Wang, P., Yoo, B., Kiupel, M., Sempere, L., Medarova, Z., and Moore, A. (2022). Case report: MicroRNA-10b as a therapeutic target in feline metastatic mammary carcinoma and its implications for human clinical trials. Front. Oncol., 12.10.3389/fonc.2022.959630 ↗
30. Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis10.1038/onc.2012.173 ↗
31. Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer10.1158/0008-5472.CAN-15-0888 ↗
32. Therapy targeted to the metastatic niche is effective in a model of stage IV breast cancer10.1038/srep45060 ↗
33. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma10.1038/s41588-018-0105-0 ↗
34. Optimization of Glioblastoma Mouse Orthotopic Xenograft Models for Translational Research
35. The clinical significance of radiological changes associated with gliadel implantation in patients with recurrent high grade glioma10.1038/s41598-022-27128-4 ↗
36. QuPath: Open source software for digital pathology image analysis10.1038/s41598-017-17204-5 ↗
37. The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-1010.3233/CBM-2009-0579 ↗
38. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model10.1148/radiology.214.2.r00fe19568 ↗
39. Novel membrane-permeable contrast agent for brain tumor detection by MRI10.1002/mrm.22216 ↗
40. MicroRNAs as therapeutic targets in human cancers10.1002/wrna.1229 ↗
41. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer10.1038/nature06174 ↗
42. Extensive modulation of a set of microRNAs in primary glioblastoma10.1016/j.bbrc.2005.07.030 ↗
43. Stepwise detection and evaluation reveal miR-10b and miR-222 as a remarkable prognostic pair for glioblastoma10.1038/s41388-019-0867-6 ↗
44. Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
45. Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors by using ferumoxtran-10
46. Covalent nano delivery systems for selective imaging and treatment of brain tumors10.1016/j.addr.2017.06.002 ↗
47. Radiolabeling and PET-MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastatic lesions in a murine model of metastatic breast cancer10.1186/s12645-021-00089-5 ↗
48. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent10.1097/01.rli.0000197669.80475.dd ↗
49. Chelate-free metal ion binding and heat-induced radiolabeling of iron oxide nanoparticles10.1039/C4SC02778G ↗
50. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: Implications for magnetic resonance imaging10.1007/s00441-004-0884-8 ↗
51. Long-term biodistribution and biocompatibility investigation of dextran-coated magnetite nanoparticle using mice as the animal model10.1166/jbn.2012.1376 ↗
52. Metabolic pathway and distribution of superparamagnetic iron oxide nanoparticles: In vivo study
53. In vivo imaging of immune rejection in transplanted pancreatic islets10.2337/db06-0484 ↗
54. Monitoring radiation-induced changes in bone marrow histopathology with ultra-small superparamagnetic iron oxide (USPIO)-enhanced MRI10.1002/(SICI)1522-2586(199905)9:5<643::AID-JMRI5>3.0.CO;2-A ↗
55. T1 and T2 relaxivity of intracellular and extracellular USPIO at 1.5T and 3T clinical MR scanning10.1007/s00330-005-0031-2 ↗
56. Design of nanodrugs for miRNA targeting in tumor cells10.1166/jbn.2014.1795 ↗
57. Ablation of miR-10b Suppresses Oncogene-Induced Mammary Tumorigenesis and Metastasis and Reactivates Tumor-Suppressive Pathways10.1158/0008-5472.CAN-16-1571 ↗
58. MGMT promoter methylation status testing to guide therapy for glioblastoma: Refining the approach based on emerging evidence and current challenges10.1093/neuonc/noy132 ↗
59. Yoo, B., Greninger, P., Stein, G.T., Egan, R.K., McClanaghan, J., Moore, A., Benes, C.H., and Medarova, Z. (2018). Potent and selective effect of the mir-10b inhibitor MN-anti-mir10b in human cancer cells of diverse primary disease origin. PLoS ONE, 13.10.1371/journal.pone.0201046 ↗
60. Tumor microenvironment in glioblastoma: Current and emerging concepts